This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Biegel, J. A. Articles by Emanuel, B. S. Search for Related Content PubMed PubMed Citation Articles by Biegel, J. A. Articles by Emanuel, B. S.

Evidence for a 17p Tumor Related Locus Distinct from p53 in Pediatric Primitive Neuroectodermal Tumors¹

Division of Human Genetics and Molecular Biology, The Children's Hospital of Philadelphia [J. A. B., C. D. B., B. S. E.]; Department of Pediatrics, University of Pennsylvania School of Medicine [J. A. B., B. S. E.]; and Departments of Human Genetics [B. S. E.] and Pathology and Laboratory Medicine [F. G. B.], Hospital of the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104

Primitive neuroectodermal tumors of the central nervous system are the most common malignant brain tumors in children. Cytogenetic analysis of these tumors has demonstrated alterations of chromosome 17, in particular isochromosome 17q, as the most frequent chromosomal abnormality detected. Since the consistent loss of a specific chromosomal region in a given tumor type most likely indicates the presence of a tumor related gene in that region, we undertook a combined molecular and cytogenetic approach to examine alterations of chromosome 17 in primitive neuroectodermal tumors. Seven of 14 tumors analyzed demonstrated loss of alleles for loci on 17p. In three of the seven tumors tested, a loss in copy number was observed for only the most telomeric locus on 17p13.3, D17S34. Limited sequence analysis of the same seven tumors did not reveal mutations in four highly conserved coding regions of the p53 gene. These data suggest a new tumor associated locus on 17p distinct from and distal to TP53, which is involved in the initiation or progression of at least a subset of primitive neuroectodermal tumors.

¹ This work was supported by the NIH (CA-46274) and the Association for Brain Tumor Research.

² To whom requests for reprints should be addressed, at Division of Human Genetics and Molecular Biology, The Children's Hospital of Philadelphia, 34th and Civic Center Blvd., Philadelphia, PA 19104.

Received 1/10/92. Accepted 4/ 6/92.

This article has been cited by other articles:

				K. Toyo-oka, T. J. Bowen, S. Hirotsune, Z. Li, S. Jain, S. Ota, L. E. Lozach, I. G. Bassett, J. Lozach, M. G. Rosenfeld, et al. Mnt-Deficient Mammary Glands Exhibit Impaired Involution and Tumors with Characteristics of Myc Overexpression Cancer Res., June 1, 2006; 66(11): 5565 - 5573. [Abstract] [Full Text] [PDF]

				F. Mendrzyk, B. Radlwimmer, S. Joos, F. Kokocinski, A. Benner, D. E. Stange, K. Neben, H. Fiegler, N. P. Carter, G. Reifenberger, et al. Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma J. Clin. Oncol., December 1, 2005; 23(34): 8853 - 8862. [Abstract] [Full Text] [PDF]

				V P Collins Brain tumours: classification and genes J. Neurol. Neurosurg. Psychiatry, June 1, 2004; 75(suppl_2): ii2 - ii11. [Full Text] [PDF]

				B. R. Rood, H. Zhang, D. M. Weitman, and P. H. Cogen Hypermethylation of HIC-1 and 17p Allelic Loss in Medulloblastoma Cancer Res., July 1, 2002; 62(13): 3794 - 3797. [Abstract] [Full Text] [PDF]

				A. J. Janss, A. Maity, C.-B. Tang, R. J. Muschel, W. G. McKenna, L. Sutton, and P. C. Phillips Decreased cyclin B1 expression contributes to G2 delay in human brain tumor cells after treatment with camptothecin Neuro-oncol, January 1, 2001; 3(1): 11 - 21. [Abstract] [PDF]

				W. Bruening, A. H. Prowse, D. C. Schultz, M. Holgado-Madruga, A. Wong, and A. K. Godwin Expression of OVCA1, a Candidate Tumor Suppressor, Is Reduced in Tumors and Inhibits Growth of Ovarian Cancer Cells Cancer Res., October 1, 1999; 59(19): 4973 - 4983. [Abstract] [Full Text] [PDF]

				C. Mejia, A. Pellin, S. Navarro, V. Castel, and A. Llombart-Bosch A New Mutation of the p53 Gene in Human Neuroblastoma, Not Correlated with N-myc Amplification International Journal of Surgical Pathology, July 1, 1999; 7(3): 149 - 154. [Abstract] [PDF]

				A. M. Adesma Topical Review: Molecular Heterogeneity in Medulloblastoma With Implications for Differing Tumor Biology J Child Neurol, July 1, 1999; 14(7): 411 - 417. [Abstract] [PDF]

				J. A. Biegel Cytogenetics and molecular genetics of childhood brain tumors Neuro-oncol, April 1, 1999; 1(2): 139 - 151. [Abstract] [PDF]

				J. A. Meyerhardt, K. Caca, B. C. Eckstrand, G. Hu, C. Lengauer, S. Banavali, A. T. Look, and E. R. Fearon Netrin-1: Interaction with Deleted in Colorectal Cancer (DCC) and Alterations in Brain Tumors and Neuroblastomas Cell Growth Differ., January 1, 1999; 10(1): 35 - 42. [Abstract] [Full Text]

				H.-K. G. Shu, M. M. Kim, P. Chen, F. Furman, C. M. Julin, and M. A. Israel The intrinsic radioresistance of glioblastoma-derived cell lines is associated with a failure of p53 to induce p21BAX expression PNAS, November 24, 1998; 95(24): 14453 - 14458. [Abstract] [Full Text] [PDF]

				S S Chong, A Tanigami, A V Roschke, and D H Ledbetter 14-3-3 epsilon has no homology to LIS1 and lies telomeric to it on chromosome 17p13.3 outside the Miller-Dieker syndrome chromosome region. Genome Res., August 1, 1996; 6(8): 735 - 741. [Abstract] [PDF]

				G. M. Brodeur The NF1 Gene in Myelopoiesis and Childhood Myelodysplastic Syndromes N. Engl. J. Med., March 3, 1994; 330(9): 637 - 639. [Full Text]